Company
TransThera Sciences
2 active trials that select patients by a biomarker on marked.bio, across 1 biomarker; 2 in phase 3.
Counts only trials this company leads as sponsor, not partnered or academic trials of its drugs.
Biomarkers
Drugs in these trials
Targeted, immune and antibody-drug-conjugate therapies named in the company's active biomarker-selected trials (including other companies' drugs used in combination).
Upcoming readouts
Active phase 2 and 3 trials whose primary completion date falls in the next 12 months, according to the sponsor.
- 2026-12 Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma Phase 3 · FGFR3 alteration (mutation or fusion), FGFR2 fusion or rearrangement
Trials
2 of 3 trials shown
-
Efficacy and Safety of TT-00420 (Tinengotinib) Tablets Versus Chemotherapy in Patients With Advanced Intrahepatic Cholangiocarcinoma Harboring FGFR2 Fusions/Rearrangements or Mutations
tinengotiniboxaliplatinfluorouracilleucovorinirinotecancapecitabine
The presence of FGFR2 gene fusion/rearrangement or mutation must be confirmed by detection using tumor tissue samples provi…
FGFR2 fusion or rearrangementIntrahepatic Cholangiocarcinoma (Icc), Advanced Cholangiocarcinoma
-
Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma
tinengotinibPhysician's Choice
Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma
FGFR3 alteration (mutation or fusion)FGFR2 fusion or rearrangementCholangiocarcinoma
-
Study to Evaluate the Efficacy and Safety of TT-00420 (Tinengotinib) in Cholangiocarcinoma
Cohort B: other FGFR alterations, including FGFR2 mutations and FGFR1/3 alterations, including fusions
FGFR3 alteration (mutation or fusion)FGFR2 fusion or rearrangementCholangiocarcinoma, FGFR2 Fusion, FGFR2 Gene Mutation, FGFR1 Alteration
No trials match these filters.